Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (12432)	12/11/1999 9:27:00 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

I think that if any other biotech company announced this research their stock would go up 40%. But because XOMA lost a shareholder suit it probably is correct to not be involved in promoting the news with a p.r. piece. I do wonder if any of this information is already priced into the stock. I honestly think not. Really believe that the institutions analyst that follow XOMA don't know as much about what XOMA is doing as many on various boards do. To be fair they may well know a heck of a lot more about what the price is likely to do, and when to buy. Years ago Sturza said don't buy until after the results are out. Sturza was right, and I and others were wrong. BTW I think perhaps two others, besides Carroll, participating in the research you brought to our attention are XOMA people. Not sure but think so. Again, great find. Thanks for sharing. Going to take it to school with me on Monday for show and tell.